EE05452B1 - Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid - Google Patents
Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitoridInfo
- Publication number
- EE05452B1 EE05452B1 EEP200400040A EEP200400040A EE05452B1 EE 05452 B1 EE05452 B1 EE 05452B1 EE P200400040 A EEP200400040 A EE P200400040A EE P200400040 A EEP200400040 A EE P200400040A EE 05452 B1 EE05452 B1 EE 05452B1
- Authority
- EE
- Estonia
- Prior art keywords
- benzothiophenes
- benzofurans
- apob
- triamide
- mtp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30164401P | 2001-06-28 | 2001-06-28 | |
| PCT/IB2002/001876 WO2003002533A1 (en) | 2001-06-28 | 2002-05-24 | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200400040A EE200400040A (et) | 2004-06-15 |
| EE05452B1 true EE05452B1 (et) | 2011-08-15 |
Family
ID=23164253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200400040A EE05452B1 (et) | 2001-06-28 | 2002-05-24 | Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid |
Country Status (47)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
| CN1880304B (zh) * | 2001-06-28 | 2010-11-24 | 辉瑞产品公司 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
| EP1469989B1 (en) * | 2002-01-02 | 2011-12-14 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates |
| CA2515368A1 (en) * | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| EP1631271A4 (en) * | 2003-05-20 | 2007-12-12 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR DISPENSING CATECHOLIC BUTANES FOR THE TREATMENT OF TUMORS |
| JP5133561B2 (ja) | 2003-06-19 | 2013-01-30 | メルク セローノ ソシエテ アノニム | プリオン変換を調節する因子の使用 |
| JP2007511500A (ja) * | 2003-11-14 | 2007-05-10 | ファイザー・プロダクツ・インク | 肥満治療のためのｍｔｐ阻害剤の固体非晶性分散体 |
| BRPI0507462A (pt) | 2004-02-04 | 2007-07-10 | Pfizer Prod Inc | compostos de quinolina substituìdos |
| SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
| FR2873694B1 (fr) | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
| WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2006088798A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
| CA2609783A1 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| DE102005027274A1 (de) * | 2005-06-08 | 2006-12-14 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
| US7417066B2 (en) | 2005-06-08 | 2008-08-26 | Schering Ag | Inhibitors of soluble adenylate cyclase |
| CA2617654A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| CA2626461A1 (en) * | 2005-10-18 | 2007-04-26 | Aegerion Pharmaceuticals | Compositions for lowering serum cholesterol and/or triglycerides |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| EP1973575B1 (en) | 2005-12-22 | 2019-07-24 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| CN101460489A (zh) * | 2006-04-07 | 2009-06-17 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| MX2009004314A (es) | 2006-11-13 | 2009-05-05 | Pfizer Prod Inc | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| AU2007338625A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor |
| WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| DK2118206T3 (en) | 2007-02-09 | 2018-06-18 | Visen Medical Inc | POLYCYCLOF COLORS AND APPLICATION THEREOF |
| JP4827986B2 (ja) | 2007-06-08 | 2011-11-30 | マンカインド コーポレ−ション | ＩＲＥ−１αインヒビター |
| WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
| WO2009090210A2 (en) * | 2008-01-16 | 2009-07-23 | Janssen Pharmaceutica Nv | Combination of metformin and an mtp inhibitor |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| JP5711151B2 (ja) * | 2010-01-06 | 2015-04-30 | 武田薬品工業株式会社 | インドール誘導体 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
| EP2665708A4 (en) * | 2011-01-20 | 2014-07-09 | Univ Colorado Regents | MODULATORS OF THE TLR3 / DSRNA COMPLEX AND APPLICATIONS THEREOF |
| CN102108070B (zh) * | 2011-01-26 | 2013-05-22 | 上海优贝德生物医药有限公司 | 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法 |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| EP2963013A4 (en) | 2013-02-27 | 2016-09-14 | Shionogi & Co | INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH |
| WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| CN103880797B (zh) * | 2014-03-26 | 2015-12-02 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
| EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| LT3203840T (lt) | 2014-10-06 | 2020-10-26 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai |
| US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3812379A1 (en) | 2016-12-09 | 2021-04-28 | Vertex Pharmaceuticals Incorporated | Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022900A (en) | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
| US4397855A (en) | 1981-06-26 | 1983-08-09 | Warner-Lambert Company | 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method |
| US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| US5416009A (en) | 1991-01-23 | 1995-05-16 | The United States Of America | Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis |
| CA2091102C (en) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| GB9225141D0 (en) | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| ES2191706T3 (es) | 1995-06-07 | 2003-09-16 | Pfizer | Derivados de tetrahidro-isoquinolinil-6-il amida del acido bifenil-2-carboxilico, su preparacion y su uso como inhibidores de la proteina de transferencia de trigliceridos microsomal y/o secrecion de apolipoproteina b (apo b). |
| MX9709914A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
| CA2244729C (en) | 1996-02-02 | 2005-08-23 | Merritt, Brigitte | Device for processing a strand of plastic material |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| WO1998023593A1 (en) | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
| AU5513298A (en) | 1996-12-20 | 1998-07-17 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| SI1042287T1 (en) | 1997-12-24 | 2005-10-31 | Aventis Pharma Deutschland Gmbh | Indole derivatives as inhibitors of factor xa |
| EP1080724A4 (en) | 1998-05-22 | 2004-06-23 | Nippon Shinyaku Co Ltd | COMPOSITIONS FOR REDUCING MTP ACTIVITY |
| CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| JP2003502314A (ja) * | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE19945594A1 (de) | 1999-09-23 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| DE19963235A1 (de) | 1999-12-27 | 2001-07-05 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| ES2240420T3 (es) | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| GB0013346D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| US20020032238A1 (en) | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2816940A1 (fr) | 2000-11-23 | 2002-05-24 | Lipha | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation |
| GB0109287D0 (en) | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| CN1880304B (zh) * | 2001-06-28 | 2010-11-24 | 辉瑞产品公司 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
| RU2293721C2 (ru) | 2002-02-28 | 2007-02-20 | Джапан Тобакко Инк. | Сложноэфирные соединения и их применение в медицине |
-
2002
- 2002-05-24 CN CN2006100941142A patent/CN1880304B/zh not_active Expired - Fee Related
- 2002-05-24 PT PT02780923T patent/PT1404653E/pt unknown
- 2002-05-24 UA UA20031212657A patent/UA75660C2/uk unknown
- 2002-05-24 DK DK02780923T patent/DK1404653T3/da active
- 2002-05-24 EE EEP200400040A patent/EE05452B1/xx not_active IP Right Cessation
- 2002-05-24 ES ES02780923T patent/ES2307799T3/es not_active Expired - Lifetime
- 2002-05-24 CZ CZ20033558A patent/CZ20033558A3/cs unknown
- 2002-05-24 EA EA200301310A patent/EA007008B1/ru not_active IP Right Cessation
- 2002-05-24 KR KR1020057025027A patent/KR100575944B1/ko not_active IP Right Cessation
- 2002-05-24 JP JP2003508914A patent/JP4139325B2/ja not_active Expired - Lifetime
- 2002-05-24 AT AT02780923T patent/ATE405548T1/de active
- 2002-05-24 PL PL02367680A patent/PL367680A1/xx unknown
- 2002-05-24 HU HU0400348A patent/HU229551B1/hu not_active IP Right Cessation
- 2002-05-24 MX MXPA03011707A patent/MXPA03011707A/es active IP Right Grant
- 2002-05-24 KR KR1020037017167A patent/KR100575919B1/ko not_active IP Right Cessation
- 2002-05-24 NZ NZ528752A patent/NZ528752A/en not_active IP Right Cessation
- 2002-05-24 AU AU2002307839A patent/AU2002307839B2/en not_active Ceased
- 2002-05-24 OA OA1200300327A patent/OA12626A/en unknown
- 2002-05-24 EP EP02780923A patent/EP1404653B1/en not_active Expired - Lifetime
- 2002-05-24 DE DE60228447T patent/DE60228447D1/de not_active Expired - Lifetime
- 2002-05-24 CA CA002451474A patent/CA2451474C/en not_active Expired - Fee Related
- 2002-05-24 TN TNPCT/IB2002/001876A patent/TNSN03146A1/fr unknown
- 2002-05-24 SI SI200230732T patent/SI1404653T1/sl unknown
- 2002-05-24 GE GE5350A patent/GEP20053720B/en unknown
- 2002-05-24 GE GEAP20027236A patent/GEP20063720B/en unknown
- 2002-05-24 WO PCT/IB2002/001876 patent/WO2003002533A1/en active IP Right Grant
- 2002-05-24 IL IL15851602A patent/IL158516A0/xx not_active IP Right Cessation
- 2002-05-24 RS YUP-1004/03A patent/RS50712B/sr unknown
- 2002-05-24 SK SK1610-2003A patent/SK287806B6/sk not_active IP Right Cessation
- 2002-05-24 BR BR0210616-7A patent/BR0210616A/pt active Search and Examination
- 2002-05-24 CN CN028130219A patent/CN1522246B/zh not_active Expired - Fee Related
- 2002-06-20 US US10/177,858 patent/US6720351B2/en not_active Expired - Fee Related
- 2002-06-21 TW TW091113664A patent/TWI313264B/zh not_active IP Right Cessation
- 2002-06-21 TW TW094146513A patent/TW200628447A/zh unknown
- 2002-06-26 AR ARP020102408A patent/AR036158A1/es active IP Right Grant
- 2002-06-26 MY MYPI20022415A patent/MY129328A/en unknown
- 2002-06-27 UY UY27360A patent/UY27360A1/es unknown
- 2002-06-27 PE PE2002000580A patent/PE20030135A1/es not_active Application Discontinuation
- 2002-06-27 GT GT200200136A patent/GT200200136A/es unknown
- 2002-06-27 AP APAP/P/2002/002567A patent/AP1649A/en active
- 2002-06-28 PA PA20028549301A patent/PA8549301A1/es unknown
-
2003
- 2003-08-13 US US10/639,855 patent/US6949572B2/en not_active Expired - Fee Related
- 2003-08-13 US US10/639,854 patent/US6979692B2/en not_active Expired - Fee Related
- 2003-10-07 ZA ZA200307818A patent/ZA200307818B/en unknown
- 2003-10-09 IS IS6988A patent/IS2603B/is unknown
- 2003-11-17 CR CR7151A patent/CR7151A/es not_active Application Discontinuation
- 2003-12-16 NO NO20035607A patent/NO326700B1/no not_active IP Right Cessation
- 2003-12-17 HR HR20031051A patent/HRP20031051B1/xx not_active IP Right Cessation
- 2003-12-22 MA MA27457A patent/MA27045A1/fr unknown
- 2003-12-22 BG BG108487A patent/BG108487A/bg unknown
- 2003-12-23 EC EC2003004925A patent/ECSP034925A/es unknown
-
2004
- 2004-09-14 HK HK04106993.0A patent/HK1064369A1/xx not_active IP Right Cessation
- 2004-09-14 HK HK07101214.1A patent/HK1096665A1/xx not_active IP Right Cessation
-
2005
- 2005-08-02 US US11/196,563 patent/US7482368B2/en not_active Expired - Fee Related
-
2006
- 2006-02-10 US US11/351,571 patent/US7348355B2/en not_active Expired - Fee Related
-
2008
- 2008-10-13 CY CY20081101126T patent/CY1108407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE05452B1 (et) | Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid | |
| EE200300385A (et) | 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid | |
| NO20014823D0 (no) | Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode | |
| LTPA2014028I1 (lt) | Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai | |
| CY2013005I2 (el) | Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων | |
| MA27001A1 (fr) | Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 | |
| DE60221886D1 (de) | 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen | |
| ATE299881T1 (de) | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren | |
| DE60232994D1 (de) | Inhibitoren von mitotischem kinesin | |
| DE60211601D1 (de) | Bereitstellung von positionsabhängigen Inhalten | |
| NO20050563L (no) | N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon | |
| DE50102325D1 (de) | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung zur hemmung der hormonsensitiven lipase | |
| DE60110232D1 (de) | Neue verwendung von lipase-inhibitoren | |
| DE60234956D1 (de) | System zum transport von unbestrahlten kernbrennstabbündeln | |
| EE200300266A (et) | Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid | |
| NO20042012L (no) | Sammensetning og fremgangsmate for behandling av diabetes | |
| NO20014222D0 (no) | Fremgangsmåte for behandling av COPD | |
| DE60127648D1 (de) | Methode und Einrichtung zur Beeinflussung von Lagerbelastungen | |
| DE60025069D1 (de) | Methode zur Verbesserung der Stabilität von aromatischen Polycarbodiimiden | |
| NO20015791D0 (no) | Arrangement og fremgangsmåte for definering og kontroll av meldingsdistribusjon | |
| FI20010611A0 (fi) | Menetelmä puutavaran kuivaamiseksi | |
| FI20020561A (fi) | Menetelmä kuitumassan kuituominaisuuksien säätämiseksi | |
| FI20012399A (fi) | Menetelmä ja järjestelmä sisällön aktivoimiseksi | |
| NO20015203D0 (no) | Isolerbar duk og fremgangsmåte for isolering av duk | |
| FI20010384A0 (fi) | Menetelmä massan valkaisussa ja massan valkaisulaitteisto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC1A | Change of owner name | ||
| GB1A | Change in the ownership or in the address of the owner | ||
| HC1A | Change of owner name | ||
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20150524 |